A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer.
We investigated the application of a mimetic 20 amino acid peptide derived from type IV collagen for treatment of breast cancer. We showed that the peptide induced a decrease of proliferation, adhesion, and migration of endothelial and tumor cells in vitro. We also observed an inhibition of triple negative MDA-MB-231 xenograft growth by 75% relative to control when administered intraperitoneally for 27 days at 10 mg/kg. We monitored in vivo the changes in vascular properties throughout the treatment using MRI and found that the vascular volume and permeability surface area product decreased significantly. The treatment also resulted in an increase of caspase-3 activity and in a reduction of microvascular density. The multiple mode of action of this peptide, i.e., anti-angiogenic, and anti-tumorigenic, makes it a viable candidate as a therapeutic agent as a monotherapy or in combination with other compounds.
Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America.
Elena V
EV
Rosca
Johns Hopkins University In-vivo Cellular and Molecular Imaging Center Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America.
Marie-France
MF
Penet
Johns Hopkins University In-vivo Cellular and Molecular Imaging Center Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America.
Noriko
N
Mori
Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America.
Jacob E
JE
Koskimaki
Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America.
Esak
E
Lee
Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America.
Niranjan B
NB
Pandey
Johns Hopkins University In-vivo Cellular and Molecular Imaging Center Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America.
Zaver M
ZM
Bhujwalla
Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America.
Aleksander S
AS
Popel
D000595:Amino Acid Sequence; D020533:Angiogenesis Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D024141:Collagen Type IV / Q000737:chemistry*; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D057786:Peptidomimetics / Q000737:chemistry* / Q000494:pharmacology*; D064726:Triple Negative Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
D020533:Angiogenesis Inhibitors; D024141:Collagen Type IV; D057786:Peptidomimetics